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Abstract
Heterozygous mutations in p63 are associated with split hand/foot malformations (SHFM), orofacial clefting, and ectodermal 
abnormalities. Elucidation of the p63 gene network that includes target genes and regulatory elements may reveal new 
genes for other malformation disorders. We performed genome-wide DNA-binding profiling by chromatin immunopre- 
cipitation (ChIP), followed by deep sequencing (ChlP-seq) in primary human keratinocytes, and identified potential target 
genes and regulatory elements controlled by p63. We show that p63 binds to an enhancer element in the SHFM1 locus on 
chromosome 7q and that this element controls expression of DLX6 and possibly DLX5, both of which are important for limb 
development. A unique micro-deletion including this enhancer element, but not the DLX5/DLX6 genes, was identified in a 
patient with SHFM. Our study strongly indicates disruption of a non-coding cis-regulatory element located more than 
250 kb from the DLX5/DLX6 genes as a novel disease mechanism in SHFM1. These data provide a proof-of-concept that the 
catalogue of p63 binding sites identified in this study may be of relevance to the studies of SHFM and other congenital 
malformations that resemble the p63-associated phenotypes.
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Introduction
The p63 protein encoded by the TP63 gene is a transcription 
factor of the p53 family and functions as a master regulator of 
ectodermal development. The key function of p63 during 
ectodermal development is underscored by phenotypic features 
in p63  knockout mice [1,2] and in p63  knock-down zebrafish [3,4]. 
The developmental abnormalities in animal models are reminis­
cent of those in p63 -associated human disorders. Heterozygous 
mutations in p63  give rise to at least seven dominantly inherited 
clinical conditions with three major characteristics, ectrodactyly 
(also known as split hand/foot malformation, SHFM), orofacial 
clefting and ectodermal dysplasia with defects in skin, hair, teeth, 
nails and exocrine glands [5,6]. There is a clear genotype- 
phenotype correlation in p63-associated disorders [7]. The most
prom inent of these disorders is the Ectrodactyly Ectodermal 
dysplasia and Cleft lip/palate syndrome (EEC, O M IM  604292) 
which combines all of the three phenotypic hallmarks and is 
almost invariably caused by missense mutations in the DNA 
binding domain ofp 6 3 . Ankyloblepharon Ectodermal defects Cleft 
lip/palate syndrome (AEC, O M IM  106260) is caused by 
mutations in the SAM domain of the p63 that is involved in 
protein interaction. Nonetheless, mutations of p63  can explain 
only a minority of patients with only one of the three cardinal 
features, such as in patients with isolated SHFM (~10%) and in 
patients with isolated cleft lip/palate (~0.1%) [7]. There remains a 
large group of ectodermal dysplasia syndromes with phenotypes 
that resemble p63-associated syndromes [8]. The genetic basis of 
many of these clinically related conditions, referred to as the p63  
phenotype network, is presently unknown.
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Author Sum m ary
Mammalian embryonic development requires precise 
control of gene expression in the right place at the right 
time. One level of control of gene expression is through 
cis-regulatory elements controlled by transcription factors. 
Deregulation of gene expression by mutations in such cis- 
regulatory elements has been described in developmental 
disorders. Heterozygous mutations in the transcription 
factor p63 are found in patients with limb malformations, 
cleft lip/palate, and defects in skin and other epidermal 
appendages, through disruption of normal ectodermal 
development during embryogenesis. We reasoned that 
the identification of target genes and cis-regulatory 
elements controlled by p63 would provide candidate 
genes for defects arising from abnormally regulated 
ectodermal development. To test our hypothesis, we 
carried out a genome-wide binding site analysis and 
identified a large number of target genes and regulatory 
elements regulated by p63. We further showed that one of 
these regulatory elements controls expression of DLX6 and 
possibly DLX5 in the apical ectodermal ridge in the 
developing limbs. Loss of this element through a micro­
deletion was associated with split hand foot malformation 
(SHFM1). The list of p63 binding sites provides a resource 
for the identification of mutations that cause ectodermal 
dysplasias and malformations in humans.
There is ample evidence that diseases clustering within such 
phenotype networks are caused by mutations in functionally 
related genes that constitute a gene network [9-11]. Elucidation of 
functional interactions among genes within the p63  gene network, 
their encoded proteins and regulatory elements which control 
expression of these genes will therefore provide new candidate 
genes for genetic disorders from the p63  phenotype network. 
Identifying target genes and cis-regulatory elements controlled by 
p63 is an im portant step in dissecting the p63  gene network. 
Previous studies have focused on transcriptional target genes of 
p63 identified through individual candidate gene approaches [12­
14] or through genome-wide approaches [15-19]. However, the 
role of regulatory elements controlled by p63 in transcription has 
not yet been addressed so far.
Split hand/split foot malformation (SHFM, O M IM  183600) is 
characterized by a deficiency of the central rays of the hands and 
feet, resulting in missing or malformed digits. SHFM  may be 
isolated (non-syndromic) or be associated with other developmen­
tal anomalies (syndromic). Six distinct chromosomal loci for non- 
syndromic SHFM  have been reported. Specific gene mutations 
have been identified in SHFM6 and SHFM4. SHFM6 (OMIM 
225300, chromosome 12q13) is caused by a homozygous 
W N T10B  mutation and it is the only autosomal recessive form 
of SHFM  [20]. SHFM4 (OMIM 605289, chromosome 3q27) is 
caused by p63  mutations [21]. Chromosomal aberrations underlie 
three other types of isolated SHFM: 7q21 deletions and re­
arrangements in SHFM1 (OM IM  183600) [22], 10q24 duplica­
tions encompassing the Dactylin gene (FBXW 4) in SHFM3 (OMIM 
600095) [23], and 2q31 deletions encompassing the H O XD  gene 
cluster in SHFM5 (OM IM  606708) [24,25]. In  addition, linkage 
analysis has mapped SHFM2 (OMIM 313350) to chromosome 
Xq26 [26].
The SHFM1 locus on chromosome 7q21 has been delineated 
by various translocations, inversions, deletions and duplications 
[27]. The smallest region of overlapping deletions in SHFM1 
patients [28] encompasses several genes: DYNC1I1, SLC25A13, 
DSS1, D L X 5  and DLX6, of which only D L X 5  and D L X 6  have been
shown to clearly play a role in early limb development. Dlx5 and 
D lx6  are highly expressed in the apical ectodermal ridge (AER) of 
the developing limbs of mice [29-31] and in the fins of zebrafish 
[3,4]. The AER is critical for limb outgrowth and patterning [32] 
and there is strong evidence that a failure to maintain the AER 
signaling is the main pathogenic mechanism in ectrodactyly [33]. 
The importance of the D L X 5 /D L X 6  genes in limb development 
has been highlighted in mouse models. Dlx5 deficient mice do not 
show any limb defects [30]. However, an SHFM-like phenotype 
has been observed when both Dlx5  and D lx6  were simultaneously 
deleted (D lx5/D lx6 2 ). The limb developmental phenotype in 
D lx5 /D lx6  /  mice could be fully rescued by overexpression of 
Dlx5 in the AER [29,34]. These observations suggest that the 
D L X 5  and D L X 6  genes cooperate in limb development by 
controlling a common developmental program. D L X 5  and D L X 6  
are further expressed in the craniofacial prominence, the otic 
vesicle and in the brain [29-31], which correlates well with the 
hearing loss and mental retardation that are present in 30% of the 
SHFM1 patients [27]. While D L X 5  and D L X 6  are obvious 
candidate genes for SHFM1, mutations have not been found in 
either of the two genes.
Here, we used a genome-wide DNA-binding profiling approach 
using Chromatin Immunoprecipitation (ChIP) followed by deep 
sequencing (ChIP-seq) in hum an primary keratinocytes to 
generate a catalogue of highly informative target genes and 
regulatory elements controlled by p63. One cis-regulatory element 
identified by DNA-binding profiling is located in the SHFM1 
critical region and acts as an enhancer element for gene expression 
mediated by p63 during embryonic limb development. O ur data 
indicate that loss of this element leads to SHFM1. This example 
illustrates that our catalogue of p63 binding sites can identify 
candidate genes and loci for the elucidation of disorders from the 
p63 phenotype network.
Results
Genome-wide p63 binding profile in human primary 
keratinocytes
The most common isoform of p63, DNp63a, is highly expressed 
in the basal layer of the epidermis that consists mainly of 
keratinocytes. We therefore established hum an primary keratino- 
cyte cultures (HKCs) from adult skin as our model system to 
elucidate p63  gene networks under physiological conditions. To 
identify target genes and regulatory elements controlled by p63, 
high-resolution global binding profiles of p63 were obtained from 
H K C cell lines established from two unrelated control individuals 
(wt1 and wt2) by ChIP-seq analysis using two antibodies 
recognizing different epitopes in p63 (4A4 and H129). Analysis 
of the sequenced reads using the peak recognition algorithm of 
Model-based Analysis of ChIP-Seq (MACS) [35] gave a highly 
significant overlap of 11,369 peaks from three profiles (P<1E-300) 
(Figure 1A). Overlapping peaks were therefore considered as a 
collection of high-fidelity p63 binding sites in HKCs. Indeed, a set 
of 17 representative binding sites of various peak heights, 
conservation scores and consensus motif scores (see below) were 
tested with independent ChIP followed by qPC R  analysis (ChIP- 
qPCR) with two antibodies (4A4 and H129) and all of them could 
be validated (Table S1, Figure S1). This confirmed that the 
obtained p63 binding profile is highly reliable.
To determine the specific p63-binding sequences in the detected 
binding sites, a de novo consensus motif prediction pipeline was 
applied to generate a Position Weight M atrix (PWM) (see 
Materials and Methods for details). A highly significant consensus 
sequence was identified that is similar to the previously reported
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Figure 1. Characterization of identified p63 binding sites. (A) A screenshot of chromosome 3 using UCSC genome browser shows similar 
DNA-binding profiles from our ChlP-seq analysis of two normal human primary keratinocyte cell lines (wt1 and wt2) with two different antibodies 
(4A4, pan-p63 and H129, a-specific). The p63 binding sites analyzed with MACS [35] using P value 1 x10~9 are shown in red, and previously reported 
p63 binding sites in ChlP-on-chip analysis [17] are shown in black. (B) The p63 motif was identified by a de novo motif analysis (see Materials and 
Methods). Based on a previously developed p53scan algorithm [37] with this newly identified p63 Positional Weight Matrix (PWM), p63scan was 
developed. (C) The performance of p63scan using the de novo identified motif shows superior sensitivity compared to previously reported p63MH 
without compromising specificity. (D) Distribution of the p63-binding site location relative to RefSeq genes. Locations of binding sites are divided 
into: TSS flanking region (5 kb upstream of TSS, first exon and first intron), intragenic region (all introns and exons except first), <25 kb (5-25 kb 
upstream or 25 kb downstream of last exon), or intergenic regions (everything else). The asterisk represents significant enrichment. 
doi:10.1371/journal.pgen.1001065.g001
p63 and p53 consensus motifs (P<1E-250) [17,18,36,37] 
(Figure 1B, Table S2). An additional significant API-like motif 
that can be bound by c-Fos and c-Jun proteins [38] was also 
identified in the detected binding sites (P<1E-50, Table S2). We 
combined our previously developed p53scan algorithm [37] with 
the newly identified p63 PWM, hereafter referred to as p63scan. 
Comparison of p63scan with the previously described motif 
algorithms p63M H  [36] and p53scan [37] showed that p63scan 
had clearly higher sensitivity for motif recognition without 
compromising the specificity (Figure 1C). A slight increase of
motif scores correlated with an increase of peak heights of the 
binding sites (Figure S2), suggesting a stronger binding of p63 to 
binding sites with higher motif scores. Using p63scan, 10,702 out 
of a total 11,369 p63 binding sites (94%) were found to contain at 
least one p63 motif (motif score 4.74, False Discovery Rate, FDR 
10%). The high percentage of motif-containing binding sites 
indicates that most binding sites identified in this study participate 
in direct binding of p63. The de novo consensus motif prediction 
pipeline was applied to the subgroup of binding sites without p63 
binding motifs to search for consensus motifs of other transcription
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factors or novel binding motifs of p63. A degenerate p63 binding 
motif was identified, and interestingly, the API motif was also 
found more strongly enriched as compared to the motif analysis of 
all binding sites (Table S2). An alternative approach also was taken 
to examine all known motifs of transcription factors in the 
TRANSFAC Professional database (version 2009.3) [39] for their 
significant over-representation (P<1E-10, after Bonferroni correc­
tion) in the p63 motif-less binding sites relative to the p63 motif- 
containing sites. Consistent with the de novo consensus motif search, 
the API motif as well as the BACH1 and BACH2 motifs that are 
similar to API was found (Table S3). These data suggest that p63 
can bind to DNA by collaborating with other transcription factors 
such as c-Jun or c-Fos. Interestingly, a previous report showed that 
p63 binds to an API responsive element to regulate Keratin 1 in 
keratinocytes in a c-Jun dependent manner [40]. No other novel 
consensus binding motifs were detected.
O ut of 11,369 binding sites, 1460 lie between 5 kb upstream of the 
transcription start site (TSS) and the end of the first intron of genes, 
referred to as TSS flanking regions, and 1908 binding sites are located 
within 25 kb distance to a gene (<25kb region) (Figure 1D). Statistical 
analysis showed that binding sites at these two chromosomal regions 
are enriched compared to genomic distributions of all binding sites 
(P<0.001). Genomic distribution of binding sites with or without a 
p63 binding motif was similar to that of all binding sites (Figure S3). In 
total, 10,895 genes had one or more p63 binding sites within 25 kb 
up- and down-stream of the gene, and they were considered as 
potential target genes (PTGs) of p63. GO annotation of these 10,895 
PTGs using DAVID Bioinformatic Resources 6.7 (NIAID, NIH) [41] 
showed a non-random distribution with enrichment in functional 
categories of biological processes, such as development, adhesion, cell 
communication and intracellular signaling cascade (Table S4). 
Binding sites with or without a p63 motif were also mapped to genes 
as separate subgroups, and 10,438 and 944 genes, respectively, have 
p63 binding sites within 25 kb of the gene. G O  annotation of genes 
mapped by binding sites with motifs resulted in very similar GO 
terms as annotation of all PTGs (Table S2). However, 944 genes 
mapped by binding sites without motifs were seemingly involved in 
slightly different biological processes (Table S4).
The p63  gene arose from two sequential gene duplications at the 
root of the vertebrates and has unambiguous orthologues only in 
that taxon [42]. We therefore assessed the evolutionary conserva­
tion of the identified binding sites and the p63 consensus motifs 
therein in aligned vertebrate genomes (PhastCons). The identified 
binding sites had higher average PhastCons Conservation Scores 
(PCCS) and were significantly more conserved than random 
sequences of the same size (Figure 2A). Moreover, PCCS of motifs
identified in the p63 binding sites were also compared to that in 
the random genomic regions. By p63scan, 10,702 motifs were 
identified in 11,369 p63 binding sites and they were more 
conserved than 4,003 motifs identified in 100,000 random 
genomic regions (Figure 2B). These data support the functionality 
of the identified p63 binding sites. We did not observe a 
correlation between PCCS and peak height (Figure S4A) or a 
clear difference in PCCS of binding sites with and without p63 
binding motifs (Figure S4B).
Association of potential p63 target genes with the 
disease phenotypes
To validate whether the identified binding sites represented 
target genes and regulatory elements relevant to thep63-associated 
and other diseases with clinical similarities, the O M IM  database 
was searched for diseases associated with the 10,895 potential 
target genes in this study. We found 904 O M IM  disease entries 
associated with these genes (Table 1, Table S5), referred to as p63 
potential target gene-associated diseases (PTG-associated diseases). 
To assess the relationship amongst PTG-associated diseases, their 
clinical features were analysed by text mining (Table S6) and 
evaluated with a similarity algorithm [43] (Table 1). The potential 
target genes of p63 do not have strong tendency to associate with 
diseases (P = 1). However, the feature terms in PTG-associated 
diseases are similar, as the similarity score of these diseases (0.284) 
is significantly higher than for a random distribution (0.200) 
(P<1E-6). This shows that PTGs are associated with diseases that 
have similar clinical phenotypes. Features associated with p63 
syndromes are enriched in the top 10% of overrepresented feature 
terms for the PTG-associated syndromes (P<1E-28). M any of 
these terms such as stem cell and epithelium reflect p63 
functioning (Table S6). This suggests that identified PTGs tend 
to cause similar disease phenotypes to p63-associated diseases. We 
did not observe a significant difference between terms derived 
from motif-containing binding sites or those from motif-less 
binding sites (Table S6). The significant similarity of disease 
features of PTGs suggests that these binding sites are relevant to 
p63-related developmental disorders.
To assess whether p63 binding sites can function as regulatory 
elements in the p63-related disease network, we focused on 
SHFM. From the human malformation disease database PO S­
SUM [44] and the Jackson Laboratory’s Mouse Genome 
Database [45], 20 genes were selected based on their localization 
in the hum an SHFM  loci (Table S7). In addition, these genes are 
known either to associate with SHFM  in hum an or to have similar 
phenotypes in mice. These genes are further referred to as SHFM-
Figure 2. Conservation of p63 binding sites and motifs in vertebrates. The percentage of p63 binding sites (y-axis) is plotted against 
decreasing cut-off values of the PhastCons Conservation Score (PCCS) (x-axis). A point on the line indicates the percentage of binding sites with that 
particular PCCS or higher. (A) Average PCS of 100-nucleotide regions centered at the summit of 11,425 p63 binding peaks (peaks 100) and that of 
100,000 100nt regions randomly chosen from the whole genome (random 100). (B) Average PCCS of 10,659 10-nt p63 motifs detected by p63scan in 
the 11,425 p63 binding peaks (peaks motifs) and of the 7,600 motifs detected in 100,000 random genomic regions (random motifs). 
doi:10.1371/journal.pgen.1001065.g002
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Table 1. Diseases associated with genes containing p63
binding sites.
Diseases associated 
w ith  genes w ith  
p63 binding sites
Total diseases in 
O M IM  associated 
w ith  genes P  valueC
No. of diseases 904 2033 1
Similarity score 
of feature termsA
0.284 0.200b <10"6
AText mined feature terms that are associated with diseases are calculated for 
their similarity scores (0, no overlap and 1, identical overlap).
BRandomized sampling of 904 diseases from OMIM database are used for the 
similarity score.
CChi-square test.
doi:10.1371/journal.pgen.1001065.t001
associated genes (Table S7). As regulatory elements can function 
over a large distance but might be blocked by insulator elements 
that are defined by C TC F binding sites [46], p63 binding sites 
were searched in broad chromosomal regions containing the 
SHFM-associated genes (up to 300kb from the genes) provided 
that no known C TC F binding sites are located between the 
binding site and the gene. With these criteria, p63 binding sites 
were identified near 12 SHFM-associated genes (Table 2). We 
propose that these p63 binding sites are potential regulatory 
elements that might contribute to SHFM.
Identification of p63 binding sites in a 7q21.3 
microdeletion in an SHFM1 patient
In the SHFM1 locus on chromosome 7, several deletions have 
been identified which invariably contain the D L X 5  and D L X 6  
genes as well as DYNC1I1, SLC25A13 and DSS1 (Figure S5) 
[28,47-51]. We identified a new patient with non-syndromic 
SHFM  (for clinical phenotype, see Materials and Methods) and a 
novel microdeletion of chromosome 7q21 by a targeted 385K 
chromosome 7-specific microarray. Surprisingly, the 880kb 
chromosomal deletion at 7q21.3 encompassed DSS1, SLC25A13 
and part of DYNC1I1 but left the SHFM1 candidate genes D L X 5  
and D L X 6  intact (Figure 3). The deletion was confirmed by
genomic qPCR analysis (Figure S6). Compared with the 
previously reported minimal chromosomal deletion (Figure S5) 
[28,47-51], the protein-coding genes in the overlapping region are 
DYNC1I1, SLC25A13 and DSS1 but these are not likely to 
contribute to the phenotype [48,52,53]. We therefore hypothe­
sized that disruption of one or more regulatory elements caused 
the SHFM1 phenotype. To test this hypothesis, p63 binding sites 
were searched in the chromosomal region spanning the D L X 5 /  
D L X 6  genes, taking into account the published CTCF binding 
sites to define the borders of enhancer activity [46]. Consistent 
with our hypothesis that D L X 5 /D L X 6  are controlled by long 
distance regulatory elements, D L X 5 /D L X 6  are located in a broad 
chromosomal region between two C TC F binding sites (chr7: 
95882240-95882467 and chr7: 96495007-96495206) spanning 
approximately 600kb (green arrows in Figure 3). This region 
contains nine putative p63 binding sites that were identified by 
our ChIP-seq analysis. These include three high peaks (SHFM1- 
BS1, -BS2 and -BS3) and six lower ones (a-f) (Figure 3, Table 3).
A p63 binding site within the SHFM1 deletion acts as an 
enhancer element in limb development
To identify the binding sites potentially im portant for limb 
development, the average PhastCons conservation score (PCCS) 
[54] of each of the nine binding sites was examined. We found that 
SHFM1-BS1 had the highest PCCS (0.456) (Table 3) that belongs 
to the top-ranking 11.6% of all 11,369 binding sites (Figure 2 and 
Figure S3). To test the functionality ofp63 binding sites, the three 
high p63 binding peaks, SHFM1-BS1, -BS2 and -BS3, were 
cloned directly in front of a luciferase reporter that is followed by 
the SV40 enhancer to test whether they are responsive to p63 
transactivation. Transient transfection assays showed that only 
SHFM1-BS1 was highly responsive to p63 (Figure 4A). Transacti­
vation activity was completely abolished by mutations in the p63 
binding motif present in SHFM1-BS1 (Figure 4B, motif shown in 
Figure 3), indicating that the observed transactivation is p63- 
specific. Mutations in the DNA-binding domain of p63 , R204W, 
R279H and R304W, that are found in EEC syndrome disrupted 
transactivation, whereas mutations found in non-syndromic 
SHFM4, K194E, and in AEC syndrome, L517F, reduced the 
transactivation activity not more than 2-fold (Figure 4C). Based on
Table 2. p63-binding sites in the chromosomal regions near SHFM-associated genes (hg 18).
Gene Chr No. o f peaks* Location o f peaks
p63 chr3 4 191025109-191025933; 191034090-191035150; 191100798-191101709; 191150499-191151202
SNX3 chr6 3 108392374-108393394; 108590949-108591991; 108862963-108863753
GJA1 chr6 1 121848018-121848681
FOXP2 chr7 6 113725067-113725994; 113840901-113841821; 114182940-114183839; 114211827-114212755; 
114250288-114251274; 114344204-114345050
DSS1 chr7 8 96029986-96030688; 96079266-96079792; 96110917-96111692; 96132694-96133405; 96177547­
96178220; 96194972-96195903; 96337204-96338894; 96388802-96389666
DLX6 chr7 3 96194972-96195903; 96337204-96338894; 96388802-96389666
DLX5 chr7 3 96194972-96195903; 96337204-96338894; 96388802-96389666
FBXW4 chr10 1 103514476-103515097
SMC3 chr10 4 112103092-112103960; 112147937-112149561; 112223542-112224445; 112243209-112244187
BRCA2 chr13 1 31904891-31905392
CDH3 chr16 2 67249490-67250527; 67259342-67260368
PORCN chrX 1 48204855-48205660
*Binding sites of p63 were searched within 300kb distance to the SHFM-associated genes and without CTCF binding sites in between. 
doi:10.1371/journal.pgen.1001065.t002
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Figure 3. A microdeletion at SHFM1 locus on chromosome 7. A screenshot of UCSC genome browser shows the p63 binding profile from two 
HKC cell lines (wt1 and wt2) with two p63 antibodies (4A4 and H129) near DLX5 and DLX6 on chromosome 7. SHFM1-BS1, -BS2 and -BS3 are three 
high peaks and a-f are low ones. SHFM1-BS2 and -BS3 are in close proximity and therefore seen as a single peak in this large genomic view. Ultra-high 
Comparative Genomic Hybridization array analysis performed with DNA of a SHFM1 patient showed a chromosomal deletion of 880 kb on 
chromosome 7 (95,390,000-96,270,000, hg18, the orange arrow) which includes DSS1, SLC25A13 and part of DYNC1I1 but not DLX5 and DLX6. 
Breakpoints and 20kb averaged log2 ratios were visualized in the genome browser. A previously reported minimal deletion determined by markers 
D7S527 and D7S1796 [28] is marked with a black arrow. Binding sites identified in this ChlP-seq study and in previous ChlP-on-chip [17] are labeled in 
red and black, respectively. CTCF binding sites revealed by previous ChlP-seq analysis [46] are labeled in green and two binding sites (chr7: 
95,882,240-95,882,467 and 96,495,007-96,495,206) that define the enhancer activity of SHFM1-BS1 are marked by green arrows. A p63 consensus 
binding motif was identified in SHFM1-BS1 with the essential cytosine and guanine bases labeled in red. 
doi:10.1371/journal.pgen.1001065.g003
the structure of the DNA-binding domain in p53 that is highly 
homologous to that in p63, lysine 194 (Q165 in p53) is located in 
the DNA-binding domain but does not have direct contact with 
DNA [5,55]. The AEC syndrome mutation L517F is located in the 
SAM domain of p63. Therefore these mutations are unlikely to 
have major effect on p63 DNA-binding. To examine the enhancer 
activity of SHFM1-BS1, -BS2 and -BS3, these elements were 
cloned in front of the SV40 prom oter or endogenous mouse Dlx5  
and D lx6  promoters that drive the luciferase gene, but no clear 
additional activation upon co-transfection of p63 was observed 
(Figure 4D and 4E and data not shown). Furthermore, in the 
absence of the enhancer, we did not detect p63 activation on the 
Dlx5  prom oter (Figure 4E, no BS) that was previously reported 
[14]. This discrepancy is probably due to different cells used in 
transient transfection assays. These results indicate that enhancer 
activity controlling expression of D L X 5  and D L X 6  genes may not 
be correctly recapitulated in a cellular system irrelevant to limb 
development.
To understand gene expression controlled by enhancer 
elements in embryonic limb development, we tested SHFM1- 
BS1, -BS2 and -BS3 in a transgenic reporter assay in zebrafish. A 
specific expression pattern of the GFP reporter controlled by 
SHFM1-BS1 but not by SHFM1-BS2 and -BS3 (data not shown) 
was observed in the AER and weakly in the ear and in the 
forebrain (Figure 5A). Expression of p63 detected by in-situ 
hybridization was only clearly localized to the AER (Figure 5B). 
The reporter expression prom oted by the SHFM1-BS1 in the 
AER that directs growth and patterning of limbs and fins 
correlated perfectly with the expression of p63, D lx5 and D lx6  
during embryonic fin or limb development (Figure 5C) [14]. To 
further determine whether gene expression regulated by SHFM1- 
BS1 depends on p63 in zebrafish, we examined the enhancer 
activity of SHFM1-BS1 in p63-knockdown embryos injected with 
a specific p63 morpholino [4]. In p63-m orphant embryos at 
48 hours post fertilization (hpf), the fin buds were severely reduced 
(mild) or absent (severe) (Figure 5C), as reported previously [3,4].
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Table 3. PhastCons Conservation Scores (PCCS) of the 
identified p63 binding sites that potentially function as 
enhancer elements.
binding sites start end PCCS*
a 96030294 96030493 0.434
b 96079364 96079563 0.234
c 96111217 96111416 0.041
d 96133015 96133214 0.010
e 96177897 96178096 0.043
BS1 96195551 96195750 0.456
BS2/BS3 96337526 96337725 0.002
f 96389201 96389400 0.088
*Average PhastCons Conservation Score of the binding sites (hg18). 
doi:10.1371/journal.pgen.1001065.t003
In the mild phenotypes, the expression of GFP induced by the 
enhancer was strongly reduced, as was the expression of the zdlx5a 
and zdlx6a genes. No fin defects were observed in embryos injected 
with a control morpholino (data not shown). Enhancer activity of 
SHFM1-BS1 was also tested in transgenic reporter assays in mice. 
Consistent with the zebrafish data, specific expression was 
observed in the AER in mouse embryos (E9.5 and E15), and the 
expression was lost when the p63-binding motif was mutated in 
SHFM1-BS1 (Figure 5D). These data showed that the specific 
expression in AER is dependent on p63. Taken together, our data 
obtained from animal models clearly demonstrated that SHFM1- 
BS1 can function as an enhancer element to control gene 
expression during embryogenesis and its activity is dependent on 
p63.
Having shown that gene expression regulated by SHFM1-BS1 
correlates with that of Dlx5  and D lx6  in zebrafish and mice, we 
tested whether SHFM1-BS1 physically interacts with the Dlx5  and 
D lx6  promoters. To do that, we used the Chromosome 
Conformation Capture technique (3C) [56] that allows detecting 
the three-dimensional proximity of two chromosomal locations 
(Figure 5E and 5F and Figure S7). In mouse embryonic limb 
tissues (E10), the interaction frequencies of SHFM1-BS1 with the 
promoter of D lx6  and with the intergenic region between Dlx5 and 
D lx6  were clearly higher than with the surrounding regions. This 
indicates that SHFM1-BS1 indeed strongly interacts with Dlx6. A 
weaker interaction of SHFM1-BS1 with D lx6  was also detectable 
in E15 limbs. In addition, SHFM1-BS1 appeared to interact with 
the intergenic region between D lx5  and D lx6  that contains highly 
conserved enhancer elements [57,58]. We did not observe clear 
interaction of SHFM1-BS1 with the prom oter of Dlx5. Taken 
together, our data show that p63 binding sites identified in HKCs 
can function as regulatory elements to control gene expression in 
embryonic limb development. We further conclude that disruption 
of regulation of D LX 5  and D L X 6  controlled by p63 likely causes 
SHFM1.
Discussion
In this study, we established the DNA-binding profiles of p63 in 
a physiologically relevant hum an cellular system to identify target 
genes and regulatory elements controlled by p63. We show that 
one of the identified p63 binding sites acts as a cis-regulatory 
element to control gene expression in the AER that correlates 
perfectly with the expression pattern of D L X 6  and D L X 5  during
embryonic development. A novel microdeletion that includes this 
binding site but leaves D L X 5  and D L X 6  intact leads to SHFM.
W ith a prevalence of 2-6%  in humans, congenital malforma­
tions represent a major medical problem [59]. Elucidation of the 
genetic basis of this heterogeneous group of disorders is important 
for genetic counseling and for basic research. Although current 
main stream genetic studies still focus on mutations in the coding 
regions of genes, disease mechanisms associated with genetic 
variants in short- or long-range regulatory elements are increas­
ingly recognized. Consistent with regulatory elements being 
required for correct spatio-temporal expression of developmental 
genes [60], mutations in non-coding cis-regulatory elements have 
been reported to cause congenital defects and have emerged as a 
disease mechanism [61-64]. Evolutionary conservation can be a 
powerful tool in the identification of regulatory elements [65-67]. 
A recent study identified a number of highly-conserved elements 
surrounding the IR F 6  gene which is known to be involved in 
several types of syndromic and non-syndromic cleft lip/palate 
[68]. In one of these elements a SNP that affects an AP-2alpha 
binding site was identified to associate with increased risk of cleft 
lip. This conserved element was able to drive the expression of a 
reporter gene during mouse orofacial development. Interestingly, 
in our ChIP-seq study we identified the very same cis-regulatory 
element as a strong p63 binding site that functions as an enhancer 
element to control expression of IR F 6  [69]. However, as only 
ultra-conserved elements are the focus of the evolutionary 
conservation approach, not all important regulatory elements 
can be identified. For example, conservation analysis in verte­
brates of the enhancer element SHFM1-BS1 in our study was not 
found as an ultra-conserved element (Figure S8 and data not 
shown), even though it is well conserved. In addition, the identity 
of the transcription factors controlling regulatory elements may 
not always be derived from the genomic sequences. O ur functional 
strategy of genome-wide p63 binding profiling does not depend on 
motif prediction or evolutionary conservation and reveals a large 
number of potential cis-regulatory elements controlled by p63.
We used hum an keratinocytes for our studies as recent work on 
transcription factor p53 revealed that responsive elements are not 
always conserved across species [70]. Moreover, primary HKC 
cell lines represent a cell type that is highly significant for p63- 
associated disorders. As many as 43% of the binding sites (2510 
out of 5807) from a p63 binding dataset using the ChIP-on-chip 
technique in a cervical carcinoma cell line [17] were also present 
in our ChIP-seq dataset. Given that different cell types and 
techniques were used in these studies, the overlap of these two 
datasets is remarkable. Nevertheless, our data from HKCs are 
highly reliable (Figure S1, Table S1) and appear to represent 
functional p63 binding sites more accurately [17].
Similar to recent reports on DNA-binding profiles of other 
gene-specific transcription factors [71-74], the number of 
identified p63 binding sites is large, which was not predicted by 
the classical paradigm of gene transactivation. O ur extensive 
bioinformatic analyses suggest that the majority of the identified 
p63 binding sites are biologically functional, as 94% of the binding 
sites contain a p63 consensus motif, and evolutionary conservation 
(Figure 2) and phenotypic similarity of PTG-associated diseases 
(Table 2) are significantly higher than random expectation. The 
binding sites are frequently located in intronic regions or at a 
distance from promoters. Thus gene-specific transcription factors 
may not only activate transcription at proximal promoters but also 
regulate gene expression at a distance perhaps by looping 
mechanisms. A recent report on the chromatin interaction map 
of the Oestrogen-Receptor-a (ERa) [75] also found long-range 
interaction of E R a binding sites and their target genes. This
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Figure 4. Transient transfection analysis of p63 binding sites at SHFM1 locus on chromosome 7. (A) The p63 binding sites SHFM1-BS1, - 
BS2 and -BS3 were tested in transient transfection assays in Saos2 cells. Transcription of the luciferase reporter was strongly activated by ANp63a 
through SHFM1-BS1 binding site but only weakly activated through -BS2 and -BS3. (B) Activation was abolished when point mutations were 
introduced into the p63 binding motif in the SHFM1-BS1 binding site where the essential cytosine and guanine bases were mutated to adenosines. 
(C) Activation was impaired by p63 EEC mutations R204W, R279H and R304W and slightly reduced by SHFM1 mutation K194E and AEC mutation 
L517F. (D) No additional activation was observed when SHFM1-BS1, -BS2 and -BS3 were cloned in front of the SV40 promoter driving luciferase. (E) No 
activation was observed on the mouse Dlx5 promoter (no BS) and when SHFM1-BS1, -BS2 and -BS3 were cloned in front of the Dlx5 promoter. 
doi:10.1371/journal.pgen.1001065.g004
proposed looping mechanism is consistent with the notion that 
SHFM1-BS1 physically interacts with the D L X 5 /D L X 6  genes that 
are located more than 250kb downstream from SHFM1-BS1 
(Figure 5E and 5F). Furthermore, binding sites identified in a 
certain cell type may also represent target genes and regulatory 
elements that can be regulated at different developmental stages in 
other cells and tissues. For example, SHFM1-BS1 was identified in 
hum an adult skin keratinocytes where D L X 5 /D L X 6  are moder­
ately expressed and their expression is not altered in EEC patient 
keratinocytes (our unpublished data). Nevertheless, SHFM1-BS1
can drive gene expression in the AER during early embryonic limb 
development.
It has been well established that p63 plays an im portant role in 
limb development, as mutations in p63  give rise to limb defects in 
complex syndromes as well as to isolated SHFM  (SHFM4) [21]. In 
this report, our data strongly indicate that p63 plays a role in 
SHFM1 by regulating D L X 5 /D L X 6  through SHFM1-BS1 that 
physically interacts with the D lx 6 promoter in the AER (Figure 5F). 
D L X 5  and D L X 6  were previously reported as target genes of p63 
as p63 binds to D lx5 /D lx6  promoters and activates these genes
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Figure 5. Functional analysis of SHFM1-BS1 to  control gene expression in zebrafish and mice. (A) SHFM1-BS1 was cloned in a reporter 
construct carrying GFP. Expression of the GFP gene in zebrafish showed that SHFM1-BS1 can control gene expression at the apical ectodermal ridge 
(AER), the ear and the forebrain. The red fluorescence expressed in the muscles in the first zebrafish panel corresponds to the positive control of 
transgenesis. (B) Expression of zp63 in the AER was detected by in situ hybridization. (C) Expression patterns of transgene GFP controlled by SHFM1- 
BS1, zdlx5a and zdlx6a were analysed by in situ hybridization in 48hpf zebrafish embryos. The same specific expression of these genes was observed 
in the AER. Treatment of p63 morpholino in zebrafish embryos resulted in mild (reduced fins) and severe (no fins) phenotypes. Accordingly, the 
expression of GFP, zdlx5a and zdlx6a is either reduced or absent in p63 morphant embryos. (D) SHFM1-BS1 was cloned in a reporter construct 
carrying the LacZ gene to generate transgenic mice. Specific expression of LacZ in the AER was shown at E9.5 and E15. Mutations in the p63 binding 
motif in SHFM1-BS1 disrupted the specific expression pattern in mice (E15). (E) A diagram shows chromosomal locations of SHFM1-BS1 and Dlx5/Dlx6. 
PCR primers used in the 3C experiment are indicated. (F) Three-dimensional physical interaction of SHFM1-BS1 to Dlx5/Dlx6 was analysed by 
Chromosome Conformation Capture (3C) technique in mouse embryonic limb tissues (E10 and E15). SHFM1-BS1 interacts strongly to the Dlx6 gene, 
as interaction frequency was clearly higher at the Dlx6 gene than at surrounding regions. Interaction frequency is expected to attenuate over distance 
to SHFM1-BS1 if there is no active interaction. Error bars represent standard errors (N = 8 or 11 for E10 or E15 limbs, respectively). 
doi:10.1371/journal.pgen.1001065.g005
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[14]. However, we did not detect p63 binding sites at the promoter 
regions of these two genes in our HKCs (Figure 3). It is plausible 
that looping of SHFM1-BS1 to the promoters may result in a 
binding signal in a ChIP experiment. We also did not observe p63 
activation on the D lx5/D lx6  promoters in transient transfection 
assays (Figure 4E and data not shown). In addition, the SHFM4 
mutations only affected transactivation mediated by SHFM1-BS1 
moderately in our transfection assay using Saos2 cells which do not 
express any endogenous p53 and p63 (Figure 4C). The disruption 
of activation on D lx5 /D lx6  promoter was previously reported in 
transfection assays using U2OS cells where endogenous wild type 
p53 is expressed [14]. The use of different cells in transfection 
assays may be responsible for the variable results of transactivation 
assays. Moreover, our observations suggest that SHFM 4 mutations 
that do not directly affect DNA-binding might disrupt protein­
protein interaction or DNA looping to the D lx5 /D lx6  promoters to 
abolish transactivation. Importantly, we showed that the enhancer 
element SHFM1-BS1 activates gene expression in the AER during 
embryogenesis and that this activation is p63 dependent.
In addition to the functional data in model systems, we provide 
genetic data that support an important role for the enhancer 
element SHFM1-BS1 in limb development by the identification of 
a novel microdeletion 7q21 in an SHFM  patient. This is a unique 
microdeletion, as the reported deletions in the SHFM1 patients so 
far all contain SHFM1-BS1 and D L X 5 /D L X 6  (Figure S5) 
[22,28,47-51,76-81]. Within the novel deletion, DYNC1I1 and 
SLC25A13 are unlikely to play a role in limb development [52,53]. 
The other gene within the minimal deletion is DSS1. DSS1 is 
expressed in the mesenchyme of the developing mouse limb [48], 
and the causative role of DSS1 in SHFM1 has not been 
demonstrated. Moreover, the expression of DSS1 in limb bud 
mesenchyme remains normal in D L X 5 /D L X 6  2 mice displaying 
typical SHFM  phenotypes [34]. O ur functional analyses support 
the notion that the enhancer element SHFM1-BS1 regulates 
expression of D L X 6  and possibly D L X 5 , and that loss of this gene 
regulation gives rise to SHFM1. This model is in agreement with 
recent reports on genomic aberrations in 7q21 that were 
associated with SHFM1. In one report, a hum an breakpoint 
located at 38 kb telomeric to DSS1 and at 258 kb centromeric to 
D L X 6  is associated with SHFM  and hearing loss phenotype 
(Figure S5) [82]. This breakpoint leaves the SHFM1-BS1 
association with DSS1 intact, but disconnects it from D LX 5  and 
D L X 6 . Interestingly in this translocation, the chromosomal context 
between the p63 binding sites SHFM1-BS2 and -BS3 with D L X 5 /  
D L X 6  is not affected, which suggests that SHFM1-BS2 and -BS3 
do not play a role in SHFM1. Another report identified a familial 
paracentric inversion-deletion 7q21 that affected a potential 
enhancer element (Figure S5) [83]. However, the spatio-temporal 
expression mediated by the identified element in this report did 
not support a role in limb development. Therefore, it is more likely 
that the SHFM  phenotype in this family is due to the dissociation 
of the D L X 5 /D L X 6  genes from SHFM1-BS1 by the inversion. It 
should be noted that in the same report, a 5,115 bp deletion 
(chr7:96,402,577-96,407,691, hg18) was identified at the break­
point. We did not observe a p63 binding site in this deletion 
(Figure 5S). O ur results and those from others thus support the 
hypothesis that SHFM1-BS1 plays an essential role in the 
regulation of D L X 5 /D L X 6 . A genetic approach to delete 
SHFM1-BS1 in mice can give an unambiguous demonstration 
of its role to control expression of Dlx5  and Dlx6 . Intriguingly, 
whereas D lx5 /D lx6  are expressed in the craniofacial region at later 
stages of development (E14-17 in mice) [29,34], absence of 
specific expression controlled by SHFM1-BS1 in craniofacial 
regions indicates that SHFM1-BS1 is not a regulatory element for
orofacial development (data not shown). Different enhancer 
elements may regulate D LX 5  and D L X 6  in these tissues. It will 
be of interest to test other less conserved p63 binding sites within 
the C TC F boundaries for a role in craniofacial development.
In summary, we have identified binding sites of p63 and taken 
the first step to build a gene network regulated by p63 with ChIP- 
seq analysis in hum an primary keratinocytes. O ur study provides 
potential target genes as well as high-resolution regulatory 
elements relevant to p63-related diseases. Reporter assays in a 
large scale to test p63 binding sites in the animal models will 
provide valuable information on functions of p63 target genes in 
ectodermal development. O ur findings strongly indicate that loss 
of the regulatory element SHFM1-BS1 identified by a p63 binding 
site constitutes a novel disease mechanism responsible for SHFM1. 
Identified target genes and regulatory elements of p63 can 
therefore be analysed for mutations and microdeletions to 
understand the disease mechanisms of unresolved diseases that 
resemble p63-associated syndromes.
Materials and Methods
Ethics statement
All procedures regarding establishing hum an primary keratino- 
cytes were approved by the ethical committee of the Radboud 
University Nijmegen Medical Centre (‘‘Commissie Mensgebonden 
Onderzoek Arnhem-Nijmegen’’). Informed consent was obtained. 
All animal work has been conducted according to relevant 
national and international guidelines.
Clinical summary of the SHFM1 patient
The patient was born with bilateral foot anomalies and had no 
other dysmorphic features, in particular no hand anomalies, 
evidence of ectodermal dysplasia, scalp defects, oral cleft, bifid 
uvula, tear duct anomalies, eyelid adhesions or abnormal nails. On 
review at age 2 years and 7 months of age, she was healthy and 
was well grown and development was within normal limits.
Human primary keratinocyte culture
Skin biopsies were taken from the trunk of healthy volunteers to 
set up the primary keratinocyte culture [84]. Keratinocyte cultures 
in Keratinocyte Growth M edium (KGM) under undifferentiated 
condition were previously described [85].
ChIP and ChlP-seq
Hum an primary keratinocytes under proliferating condition 
where p63 is expressed at the highest level were used for ChIP and 
ChIP-seq analysis. Cells were crosslinked with 1% formaldehyde 
for 10 minutes and chromatin was collected as described [86]. 
Chromatin was sonicated using a Bioruptor sonicator (Diagenode) 
for 2 times of 8 minutes at high power, 30s ON, 30s OFF. p63 
antibodies 4A4 (Abcam) and H129 (Santa Cruz) were used in 
ChIP-qPCR and ChIP-seq analyses. ChIP experiments were 
performed as previously described [37]. ChIP-seq analysis was 
performed on a Solexa Genome Analyzer (Illumina) as described 
previously [71].
ChIP-seq data analysis
All 32-bp sequence reads were uniquely mapped to the hum an 
genome NCBI build 36.1 (hg18) with zero or one mismatch using 
ELAND (Illumina), resulting in 3.2, 6 and 20 million unique reads 
for the three analyzed samples, wt1 with 4A4 ChIP, wt2 with 4A4 
ChIP and wt2 with H129 ChIP, respectively. Peak recognition was 
performed using MACS [35] with default settings and a P  value 
threshold of 1E-9, giving 18,133, 14,963 and 29,166 peaks in
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ChIP-seq tracks of wt1 with 4A4 ChIP, wt2 with 4A4 ChIP and 
wt2 with H129 ChIP, respectively. Peaks were mapped to RefSeq 
genes, downloaded from the UCSC Genome Browser (hg18), to 
determine genomic location. The ChIP-seq data and associated 
peaks have been deposited in NCBI’s Gene Expression Omnibus 
[87] and are accessible through G EO Series accession number 
GSE17611 (http://www.ncbi.nlm .nih.gov/geo/query/acc.cgipacc 
= GSE17611).
De novo motif search
To determine the p63 motif, a de novo motif prediction pipeline 
combining three motif prediction tools, MotifSampler [88], 
W eeder [89] and MDmodule [90], was run on 2273 (20%) 
randomly selected 200-bp peak sequences (centered at the peak 
summit as reported by MACS) and PWMs were generated. We 
used the ‘large’ analysis setting for Weeder. MDmodule and 
MotifSampler were each used to predict 10 motifs for each of the 
widths between 6 and 20. The significance of the predicted motifs 
was determined by scanning the remaining 80% of the peak 
sequences and two different backgrounds: a set of random 
genomic sequences with a similar genomic distribution as the 
peak sequences and a set of random sequences generated 
according to a 1st order Markov model, matching the dinucleotide 
frequency of the peak sequences. P  values were calculated using 
the hypergeometric distribution with the Benjamin-Hochberg 
multiple testing correction. All motifs with a P  value<0.001 and 
an absolute enrichment of at least >  1.5-fold compared to both 
backgrounds were determined as significant. We calculated the 
R O C  AUC for all significant motifs and chose the best performing 
motif based on the R O C  AUC (See Table S2 for the results). The 
PWM of this motif was combined with the p53scan algorithm to 
generate p63scan, using an optimal threshold, determined by the 
maximum f-measure as described previously [37]. The p63scan 
algorithm can be downloaded from http://w w w .ncm ls.eu/ 
bioinfo/p63scan/. To examine the correlation of motif score 
and peak height, all peaks were divided in quartiles according to 
peak height (the number of reads per peak). For each quartile the 
distribution of the motifs score as determined by p63scan is 
depicted as a boxplot.
Motif over-representation analysis using TRANSFAC
To detect putative transcription factor motifs reported in the 
TRANSFAC Professional database version 2009.3 [39], the 
MotifScanner program [91] was used. The search was performed 
on both strands using a 3rd-order Markov model calculated from 
the hum an promoter set of the Eukaryotic Promoter Database 
(EPD) as a background model. The param eter p  (a prior 
probability of finding one instance of the motif in a sequence) 
was set to a value of 0.5. To identify motifs that are 
overrepresented in the p63 motif-less binding sites, the binomial 
test was used. The obtained P  values were corrected for multiple 
testing (631 motifs for which sites were found in the p63-binding 
regions) using a Bonferroni correction.
Quantitative PCR
Quantitative PC R  primers were designed using Primer3 
(http://frodo.w i.m it.edu) [92], and qPCR reactions were per­
formed in the 7500 Fast Real Time PCR System apparatus 
(Applied Biosystems) by using iQ  SYBR Green Supermix (Biorad) 
according to the manufacturer’s protocol. For qPC R  of ChIP 
analysis, one primer set was used for each tested binding region 
(Table S8) and ChIP efficiency of certain binding sites was 
calculated using percentage of ChIPped DNA against input 
chromatin.
Analysis of potential target genes associated with 
phenotypic defects using human and mouse disease 
bases
Text mining-based [43] feature overrepresentation and gene to 
disease mapping were determined using the Online Mendelian 
Inheritance in M an (OMIM) disease database [93,94]. Detailed 
information can be found in supplementary information. Human 
diseases associated with SHFM  were taken from the Pictures O f 
Standard Syndromes and Undiagnosed Malformations (POS­
SUM) database [44], current as of August 2007, and mapped to 
genes through their O M IM  IDs. Mouse SHFM-associated 
phenotypes and associated genes were taken from the Jackson 
Laboratory’s Mouse Genome Database (http://w ww .inform atics. 
jax.org/) [45].
Evolutionary conservation of binding sites
To assess the evolutionary conservation of the 11,369 sites 
bound by p63, the PhastCons [54] conservation track from the 
UCSC Genome Browser was used to calculate PhastCons 
Conservation Score (PCCS). Conservation based on 44 vertebrate 
genomes was chosen because the p63 gene has 1-1 orthologs 
throughout the vertebrates [42]. The conservation for a region was 
calculated as the average conservation of each nucleotide therein. 
To analyse the correlation of PCCS and peak height, all peaks 
were divided in quartiles according to peak height (the number of 
reads per peak). For each quartile the distribution of the 
PhastCons Conservation Scores (PCCS) is depicted as a boxplot.
Mapping deletion in a SHFM patient using ultra-high 
comparative genomic hybridization
For detailed detection of chromosome 7 aberration, high 
resolution NimbleGen HG18 chromosome 7 specific 385K arrays 
were used (B3738001-00-01; Roche NimbleGen Systems, M adi­
son, Wisconsin, USA). The 385K average probe distance was 
365bp. DNA labeling, array hybridization, post-hybridization 
washes and scanning were performed according to the manufac­
turer’s instructions (Roche NimbleGen). The acquired images 
were analyzed using NimbleScan V2.4 extraction software (Roche 
NimbleGen). For each spot on the array, the log2 Cy3/Cy5 ratio 
(relative intensity of the Cy3 labeled patient DNA vs. the Cy5 
labeled male DNA reference pool of 5 healthy male individuals) 
was calculated using the segMNT algorithm, which also applied 
an automatic segment detection. A 50 x averaging window was 
generated, resulting in 20kb segments for this array. Breakpoints 
were determined with SignalMap V1.9 software (Roche Nimble- 
Gen) and 20kb averaged log2 ratios were visualized in the UCSC 
genome browser.
Constructs and transactivation assays
The genomic regions of p63 binding site peaks were amplified 
by PCR with gateway cloning primers and cloned into a modified 
ccdB-containing pGL3-Enhancer Vector, or a ccdB-containing 
pGL3-Promoter Vector, or a ccdB-containing pGL3-D lx5  Vector. 
The ccdB-containing pGL3-Dlx5  Vector was generated by 
amplification of mouse genomic DNA using primers described 
in Table S8 to obtain the mouse Dlx5  prom oter to replace the 
SV40 prom oter with BglII and HindIII sites in the ccdB-containing 
pGL3-Promoter Vector. Point mutations were introduced into 
p63-binding motifs of SHFM1-BS1 to generate m utant p63 
binding sites, where the essential cytosine and guanine bases were 
mutated to adenosine. The ANp63a wild-type (pcDNA- 
mM_ANp63a) expression plasmid has been described previously 
[85]. Point mutations were introduced into this plasmid to
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generate R204W, R279H, R304W, K194E and L517F mutations. 
Transfection and luciferase assays were described previously [85]. 
All cloning and mutagenesis primers are described in Table S8.
Transgenic reporter analyses in zebrafish and mice
H um an genomic fragments containing the SHFM1-BS1, -BS2 
and -BS3 were amplified with primers described in Table S8. The 
PCR fragments were subcloned in P C R 8 /G W /T O P O  vector and 
then transferred, through recombination using Gateway technol­
ogy, to the ZED destination vector for zebrafish transgenesis [95]. 
This vector contains the Xenopus Cardiac actin prom oter driving 
DsRed as a positive control for transgenesis. To generate the 
zebrafish transgenic embryos, we used Tol2 transposon/transpos- 
ase method [96] with minor modifications. Volume of 2-5nl of 
mixture containing 25ng/ul of transposase mRNA, 20ng/ul of 
phenol/chloroform purified ZED constructs and 0.05% phenol 
red was injected in the cell of 1 cell stage embryos. Three or more 
independent stable transgenic lines were generated for each 
construct. For the generation of transgenic mice, the genomic 
fragments with and without point mutations in p63 consensus 
motif were transferred into a vector containing the hum an 
minimal beta-globin promoter, lacZ and a SV40 polyadenylation 
signal. Constructs were linearized and the vector backbone 
removed prior to microinjection into the pronucleus of one-cell 
mouse embryos. F0 embryos of 9.5-13 dpc stages were harvested 
and stained for lacZ activity.
Morpholino injections and in situ hybridizations in 
zebrafish embryos
Once cell stage embryos were injected with 3ng of ANp63 M O
II (TCCACAGGCTCCAGGATTCTTACCC) as described pre­
viously [4]. Injected embryos were raised at 28°C in standard E3 
medium and fixed at 48 hours post fertilization in 4% parafor­
maldehyde overnight at 4°C. In situ hybridizations were carried 
out as described [97]. As a control, we injected a similar amount of 
a M O  directed against the Xenopus tropicalis olig2 gene that shows no 
match in the zebrafish genome [98].
Chromosome Conformation Capture (3C) assay
Chromosome Conformation Capture (3C) assay was per­
formed as referred in Hagege et al., 2007 [56]. Limbs of E10- and 
E15-stage mouse embryos were dissected and processed to get 
single cells preparations. Ten million isolated cells were first 
fixated with 2% formaldehyde, and then cells were lysed and 
nuclei were digested with H indIII endonuclease (Roche). After 
that, DNA was ligated with T4 DNA ligase (Promega) in low 
concentration conditions to favour intramolecular ligations. A set 
of locus specific primers close to a H indIII site (Table S8) was 
designed with Primer3 v. 0.4.0 [92]. These primers were used to 
make semi-quantitative PCRs to measure the relative enrichment 
in each ligation product. The prim er near to the BS1 enhancer 
was taken as the fixed primer, and the different interactions were 
tested using primers close to the promoters of D L X 5  and D L X 6  
genes. For each interaction two negative control primers were 
designed about 30 kb upstream and downstream the prom oter 
specific primer. PCR products were run in agarose gels and 
measured using a Typhoon scanner. Product values were related 
to a control composed of two BACs that encompass our region of 
interest.
Supporting Information
Figure S1 ChIP-qPCR analysis of p63 binding in human 
primary keratinocytes using two different p63 antibodies 4A4
(pan-p63) and H129 (a-specific). Specific binding of p63 to the 
tested binding sites was observed, including to binding sites at 
p21WAF/CIPi9 and DST which served as positive controls, but not 
to the negative controls myoglobin exon 2 (myo) and a no-gene 
region (chr11).
Found at: doi:10.1371/journal.pgen.1001065.s001 (0.16 MB PDF)
Figure S2 Correlation of motif scores to peak heights. All peaks 
were divided in quartiles according to peak height (the number of 
reads per peak). For each quartile the distribution of the motifs 
score as determined by p63scan is depicted as a boxplot.
Found at: doi:10.1371/journal.pgen.1001065.s002 (0.16 MB PDF)
Figure S3 Genomic distribution of p63 binding sites with and 
without p63 consensus binding motifs.
Found at: doi:10.1371/journal.pgen.1001065.s003 (0.13 MB PDF)
Figure S4 Correlation of PhastCons Conservation Scores 
(PCCS) to peak heights and p63 binding motifs of the p63 binding 
sites. (A) The percentage of p63 binding sites (y-axis) is plotted 
against decreasing cut-off values of the PhastCons Conservation 
Score (PCCS) (x-axis) for two groups of peaks: those with a p63 
motif and those without a p63 motif, as determined by p63scan. 
(B) All peaks were divided in quartiles according to peak height 
(the number of reads per peak). For each quartile the distribution 
of the PhastCons Conservation Scores (PCCS) is depicted as a 
boxplot.
Found at: doi:10.1371/journal.pgen.1001065.s004 (0.08 MB PDF)
Figure S5 Previously reported chr.7 deletions involved in 
SHFM1 (hg18). (A) The grey track C G H  array CNV data with 
deletion in the SHFM1 patient is compared to the minimum 
critical regions for SHFM1 based on the literature. Pale green 
tracks represent deleted intervals in patients with SHFM1 who 
have cytogenetic deletions (Del Porto et al., 1983; Tajara et al., 
1989; Morey et a l, 1990; Roberts et a l, 1991; Nunes et a l, 1994; 
McElveen et al., 1995; Montgomery et al., 2000). Dark green tracks 
represent deleted intervals in patients with SHFM1 where 
mapping has been done with STS markers (Marinoni et al., 
1995; Crackower et al., 1996; Fukushima et al., 2003; Wieland etal., 
2004). Purple tracks represent summed mapping of deletions 
combined from many patients with SHFM1 (Scherer et al., 1994; 
Tackels-Horne et al., 2001). The brown track represent a 
microdeletion at the break point of a chromosome inversion in a 
patient with SHFM1 (Brown et al., 2010). The red bar represents 
three p63 binding sites. (B) A zoomed-in view of the region 
including SHFM1-BS1, -BS2 and -BS3 and D L X 5 /6 . A 
translocation in SHFM1 that disconnects SHFM1-BS1 with 
D L X 5 /6  is depicted with a black arrow (Saitu et al., 2009).
Found at: doi:10.1371/journal.pgen.1001065.s005 (0.24 MB PDF)
Figure S6 Genomic qPCR analysis of deletion of the p63 
binding site SHFM1-BS1 in the SHFM1 patient. Genomic qPCR 
was performed to confirm the deletion in the SHFM1 patient 
revealed by C G H  analysis. Copy number was calculated against 
an internal control primer set in the CFTR  gene.
Found at: doi:10.1371/journal.pgen.1001065.s006 (0.18 MB PDF)
Figure S7 Raw data of 3C experiments in mouse limbs at E10 
and E15.
Found at: doi:10.1371/journal.pgen.1001065.s007 (0.47 MB PDF)
Figure S8 Evolutionary conservation of the p63 binding site 
SHFM1-BS1 in vertebrates. SHFM1-BS1 was examined for its 
conservation in vertebrates using USCS genome browser. The 
consensus motif of p63 is highlighted in the red box.
Found at: doi:10.1371/journal.pgen.1001065.s008 (0.19 MB PDF)
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T ab le  S1 Validation by ChIP-qPCR of detected binding sites in 
ChIP-seq analysis.
Found at: doi:10.1371/journal.pgen.1001065.s009 (0.07 MB 
DOC)
T ab le  S2 M otif analysis with a de novo motif prediction pipeline. 
Found at: doi:10.1371/journal.pgen.1001065.s010 (0.02 MB 
XLS)
T ab le  S3 The motifs significantly overrepresented in the p63 
motif-less binding sites.
Found at: doi:10.1371/journal.pgen.1001065.s011 (0.03 MB 
DOC)
T ab le  S4 The most significant G O  annotation terms of potential 
target genes of p63.
Found at: doi:10.1371/journal.pgen.1001065.s012 (0.05 MB 
DOC)
T ab le  S5 O M IM  IDs associated with genes containing p63 
binding sites.
Found at: doi:10.1371/journal.pgen.1001065.s013 (0.14 MB 
XLS)
T ab le  S6 Affected features in p63 potential target gene- 
associated diseases (PTG-associated diseases).
Found at: doi:10.1371/journal.pgen.1001065.s014 (0.37 MB 
XLS)
T ab le  S7 Genes potentially involved in SHFM mouse models or 
hum an SHFM  phenotypes.
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